Navigation Links
Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
Date:11/18/2010

KING OF PRUSSIA, Pa., Nov. 18, 2010 /PRNewswire/ -- Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved the supplemental new drug application for NEXTERONE® (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.  NEXTERONE Premixed Injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.   NEXTERONE Premixed Injection is approved in two ready-to-use dosage forms with strengths of 1.5 mg/mL (150 mg/100 mL) for rapid loading infusion and 1.8 mg/mL (360 mg/200 mL) for subsequent infusion.    

"Until now, amiodarone IV required admixture at time of use. NEXTERONE Premixed Injection overcomes the need to admix amiodarone IV, thereby eliminating the potential for medication admixture error," said Dr. Warren D. Cooper, President and CEO of Prism. "The ready-to-use packaging is designed for the storage of NEXTERONE Premixed Injection at the point of use in automated dispensing cabinets and crash carts and offers a two-year shelf life."

Manufacturer-prepared, premixed ready-to-use products represent a preferred approach, when available, to advance initiatives and professional standards for improving IV drug safety. Organizations that promote, support, and monitor implementation of practices intended to assure quality services in the hospital environment include the Joint Commission, the United States Pharmacopeia (USP) and the American Society of Health System Pharmacists (ASHP).  

NEXTERONE Premixed Injection is manufactured for Prism Pharmaceuticals, Inc. by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.

About Ventricular Fibrillation and Ventricular Tachycardia

Ventricular fibrillation is a condition in which the heart's electrical activity becomes disordered. When this happens, the heart's lower (pumping) chambers, called ventricles, contract in a rapid, unsynchronized way. (the ventricles "flutter" rather than beat). The heart pumps little or no blood. Ventricular fibrillation is very serious. Collapse and sudden cardiac death will follow in minutes unless medical help is provided immediately. 

Ventricular tachycardia is a fast or rapid heart rate that starts in the heart's lower chambers. Ventricular tachycardia may result from serious heart disease and usually requires prompt treatment.

Important Safety Information about NEXTERONE 

NEXTERONE is contraindicated in patients with: known hypersensitivity to any of the components of NEXTERONE, including iodine, or in patients with cardiogenic shock, marked sinus bradycardia, and second- or third-degree atrio-ventricular (AV) block unless a functioning pacemaker is available. If hypotension occurs, treat initially by slowing the infusion; additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion. If bradycardia and AV block occur, treat by slowing the infusion rate or discontinuing NEXTERONE. The most common adverse reactions (1–2 percent) leading to discontinuation of intravenous amiodarone therapy are hypotension, asystole/cardiac arrest/pulseless electrical activity, ventricular tachycardia (VT), and cardiogenic shock. Other important adverse reactions are torsade de pointes (TdP), congestive heart failure, pulmonary disorders, and liver function test abnormalities.

For more information about NEXTERONE, including full prescribing information, visit www.prismpharma.com.

About Prism Pharmaceuticals, Inc.

Prism Pharmaceuticals, Inc., based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products.

Prism was started in 2004 with a founding investment from Essex Woodlands Health Ventures (www.ewhv.com). In 2006, Prism secured a $68 million layered financing of equity from Essex combined with equity and a revenue interest agreement from Paul Capital Healthcare (www.paulcapitalhealthcare.com). This level of sustaining investment has enabled Prism to pursue an aggressive licensing and rapid development model resulting in the successful approval of NEXTERONE.

The worldwide rights to NEXTERONE were licensed in early 2006 from CyDex Pharmaceuticals, Inc. (www.cydexpharma.com). NEXTERONE is based on the CyDex patent-protected CAPTISOL® technology platform.

For further information, visit www.prismpharma.com.

NEXTERONE® is a registered trademark of Prism Pharmaceuticals, Inc.

CAPTISOL® is a registered trademark of CyDex

Galaxy is a registered trademark of Baxter International Inc.


'/>"/>
SOURCE Prism Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Samplify Systems Next-Generation Prism 3.0 Real-Time Compression IP Named Finalist in EDN Magazines 20th Annual Innovation Awards
2. Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
3. Prism Glasses Expand the View for Patients with Hemianopia
4. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
5. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
6. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
7. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. Vanda Pharmaceuticals Appoints Chief Financial Officer
11. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the ... 2025" report to their offering. ... The global orthopedic navigation ... 2025. Increasing geriatric population prone to orthopedic diseases is a ... over the forecast period. Osteoarthritis and osteoporosis are most common ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... The Aresty Institute of Executive Education ... to address the increasingly complex educational needs of today's global executives. Corporate ... corporate finance and will increase their ability to confidently take action in ways ...
(Date:3/30/2017)... ... 30, 2017 , ... Nutrition Education for the Public (NEP), ... join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: Exploring Issues ... educators and students inform consumers about the health benefits of eating a seafood-rich ...
(Date:3/29/2017)... ... , ... During the last week of March, Chad Kawa, MD of Revere ... the local community. , Colon cancer is the second leading cause of cancer ... it is small, confined and easier to treat. If you are 50 or older, ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 30, 2017 , ... ... , Charm City Run has announced that Mercy Medical Center will serve as the ... in the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk ...
Breaking Medicine News(10 mins):